Topics

Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With High Risk Coronary Artery Disease (FORWARD)

2019-09-18 03:27:45 | BioPortfolio

Summary

The primary objective was to evaluate the effect of treatment with evolocumab on the risk for cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization, whichever occurs first, in patients with high risk coronary artery disease.

Study Design

Conditions

Dyslipidemia

Intervention

Evolocumab

Status

Not yet recruiting

Source

Beijing Anzhen Hospital

Results (where available)

View Results

Links

Published on BioPortfolio: 2019-09-18T03:27:45-0400

Clinical Trials [194 Associated Clinical Trials listed on BioPortfolio]

Safety, Tolerability & Efficacy on LDL-C of Evolocumab in Subjects With HIV & Hyperlipidemia/Mixed Dyslipidemia

The study is divided into 2 parts. The first part of the study will be double-blinded and will last for 24 weeks. During this time, subjects will be randomized in a ratio of 2:1 to receive...

Safety and Efficacy of Evolocumab in Addition to Optimal Stable Background Statin Therapy in Chinese Subjects With Primary Hypercholesterolemia and Mixed Dyslipidemia

This study is being done to learn more about evolocumab in Chinese people with primary hypercholesterolemia or mixed dyslipidemia. This study will see if evolocumab will reduce low density...

A Double-blind, Randomized Study in Diabetic Subjects With Hyperlipidemia or Mixed Dyslipidemia

The primary hypothesis is that both dosing regimens of SC evolocumab (AMG 145) in combination with statin therapy will be well tolerated and will result in greater reduction of LDL-C in di...

A Double-blind, Randomized Study in Subjects With Type 2 Diabetes Mellitus With Hypercholesterolemia/Mixed Dyslipidemia

The purpose of this study is to evaluate the effect of 12 weeks of subcutaneous evolocumab taken monthly compared with subcutaneous placebo taken monthly on low density lipoprotein cholest...

EXpanded Combination of Evolocumab Plus Empagliflozin on Diabetes: EXCEED-BHS3 Trial

Based on the current evidence, empagliflozin could reduce cardiovascular morbidity and mortality in Diabetes Mellitus Type 2 (T2DM). Anti-PCSK9 therapy (evolocumab) can reduce the major ca...

PubMed Articles [207 Associated PubMed Articles listed on BioPortfolio]

Updated Cost-effectiveness Analysis of Evolocumab in Patients With Very High-risk Atherosclerotic Cardiovascular Disease.

In October 2018, evolocumab was made available at a reduced annual list price of $5850 in the United States. This 60% reduction was aimed at improving patient access by lowering patient copays. Shortl...

Evolocumab, a proprotein convertase subtilisin/kexin type 9 inhibitor, promotes angiogenesis in vitro.

The proprotein convertases family is involved in several physiological processes such as cell growth, migration, and angiogenesis, and also in different pathological conditions. Evolocumab, an inhibit...

Association between dyslipidemia and carotid plaque incidence in a research group: a prospective cohort study.

To assess the association and intensity of baseline dyslipidemia with the incidence of carotid plaque in a researchers group in China. A total of 716 researchers were enrolled in this prospective coh...

CME: Dyslipidemia and Cardiovascular Risk in HIV Infected Patients.

CME: Dyslipidemia and Cardiovascular Risk in HIV Infected Patients Dyslipidemia is a common problem in HIV-infected patients and can contribute to an elevated cardiovascular risk among this patient g...

Efficacy and safety of evolocumab in individuals with type 2 diabetes mellitus: primary results of the randomised controlled BANTING study.

The study aimed to examine the efficacy of 12 weeks of monthly evolocumab or placebo in lowering LDL-cholesterol (LDL-C) in individuals with type 2 diabetes and hypercholesterolaemia or mixed dyslipi...

Medical and Biotech [MESH] Definitions

A cluster of symptoms that are risk factors for CARDIOVASCULAR DISEASES and TYPE 2 DIABETES MELLITUS. The major components of metabolic syndrome include ABDOMINAL OBESITY; atherogenic DYSLIPIDEMIA; HYPERTENSION; HYPERGLYCEMIA; INSULIN RESISTANCE; a proinflammatory state; and a prothrombotic (THROMBOSIS) state.

A cluster of metabolic risk factors for CARDIOVASCULAR DISEASES and TYPE 2 DIABETES MELLITUS. The major components of metabolic syndrome X include excess ABDOMINAL FAT; atherogenic DYSLIPIDEMIA; HYPERTENSION; HYPERGLYCEMIA; INSULIN RESISTANCE; a proinflammatory state; and a prothrombotic (THROMBOSIS) state. (from AHA/NHLBI/ADA Conference Proceedings, Circulation 2004; 109:551-556)

More From BioPortfolio on "Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With High Risk Coronary Artery Disease (FORWARD)"

Quick Search

Relevant Topics

Women's Health
Women's Health - key topics include breast cancer, pregnancy, menopause, stroke Follow and track Women's Health News on BioPortfolio: Women's Health News RSS Women'...

Cardiovascular disease (CVD)
Acute Coronary Syndromes (ACS) Blood Cardiovascular Dialysis Hypertension Stent Stroke Vascular Cardiovascular disease (CVD) includes all the diseases of the heart and circulation including coronary heart disease (angina...


Searches Linking to this Trial